Clinical Trial Update: Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007 [Phase 3]

View source ↗

Summary

This update notes the completion of the Phase 3 extension study of AG-348 in adults with pyruvate kinase deficiency, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pyruvate Kinase Deficiency

Drugs mentioned

• Pyrukynd (mitapivat)

Snippet

Sponsor: Agios Pharmaceuticals, Inc. | Conditions: Pyruvate Kinase Deficiency | Phase 3 | Status: COMPLETED | Results posted: 2025-11-18